ACS Medicinal Chemistry Letters · 2023 · 10 citations · 16 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryBcl-2 Family ProteinsMacrocycle SynthesisBcl-2 InhibitionCellular PotencyIndole ChemistryIndole DerivativesMacrocyclic CompoundsMacrocyclic InhibitorsPyrazole ChemistryTherapeutic Target Identification
Myeloid cell leukemia-1 (MCL-1) is a member of the antiapoptotic BCL-2 proteins family and a key regulator of mitochondrial homeostasis. Overexpression of MCL-1 is found in many cancer cells and contributes to tumor progression, which makes it an attractive therapeutic target. Pursuing our previous study of macrocyclic indoles for the inhibition of MCL-1, we report herein the impact of both pyrazole and indole isomerism on the potency and overall properties of this family of compounds. We demonstrated that the incorporation of a fluorine atom on the naphthalene moiety was a necessary step to improve cellular potency and that, combined with the introduction of various side chains on the pyrazole, it enhanced solubility significantly. This exploration culminated in the discovery of compounds ( R a )- 10 and ( R a )- 15, possessing remarkable cellular potency and properties
16
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim, Craig H. Mermel, Dale Porter et al. · Nature · 2010 · 4.1K citations · Full text
Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death
Michael C. Wei, Wei‐Xing Zong, Emily H. Cheng et al. · Science · 2001 · 3.9K citations · Full text
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations
Medicine, Oncology, Pharmacology +11